Metastatic Colorectal Cancer | Norton Healthcare

Indication: Metastatic Colorectal Cancer

A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PDL1 positive Colorectal Cancer

Sub-indication: Gastrointestinal Cancer

Study Type: Drug Study

Principal Investigator: Michael Driscoll, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Merck & Co., Inc

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.